Home
    Disclaimer

    Opium Stats & Data

    O Pen yan Joy plant Paregoric
    Chemical Class Opioid
    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    State Liquid

    Description

    Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction.

    Mechanism of Action

    Opium produces its effects by activating specific G protein-coupled receptors in the brain, spinal cord, and peripheral nervous system. There are three major classes of opioid receptors being δ-opioid, κ-opioid and μ-opioid. Opium will generate an agonist activity which will later open the potassium channels and prevent the opening of voltage-gated calcium channels. This activity causes a reduction in neuronal excitability and inhibits the release of pain neurotransmitters. The addictive character of opium is related to the binding to the μ-opioid receptors, which will activate dopaminergic neurons in the ventral tegmental area of the midbrain and thus, enhance the dopamine release in the nucleus accumbens. This mechanism involves the reward activity of the mesolimbic dopaminergic pathway.

    Pharmacodynamics

    Opioids can reduce the intensity and unpleasant feeling of pain. The unspecific effect of opium to the different opioid receptors produce the generation of various effects such as sedation, euphoria, dysphoria, respiratory depression, constipation, pruritus, nausea, and vomiting. It is reported that the secondary effects tend to be diminished as long-term use tolerance is developed. Some reports have also shown an opioid-driven impairment of the hypothalamic function that can result in a loss of libido, impotence, and infertility. Patients have reported a sensation of stress relief even in presence of pain as well as the presence of sedation, hypoventilation, cough inhibition, prolonged apnea, myosis and respiratory obstruction. In the cardiovascular system, there are reports of peripheral vasodilatation, including cutaneous causing flushing of the face, neck, and thorax, impaired sympathetic reflexes and postural hypotension. In the gastrointestinal and urogenital system, the increase in smooth muscle tone has been shown to produce reduced peristalsis, delayed gastric emptying and urinary retention.

    Metabolism

    Opium contains 50 different alkaloid opiates. The most common metabolism of opiates is to be ultimately converted to morphine which is further converted to morphine-3,6-diglucuronide. Opioids are metabolized vastly by the enzyme CYP 2D6 and any mutation in this kind of enzyme or coadministration with drugs that interfere with this enzyme may generate a change in the metabolism speed. For years, because of this metabolism pathway, it was very hard to differentiate between illicit heroin users and involuntary exposure to poppy seeds. The original tests for this differentiations were based in the presence of morphine in urine without evidence of 6-monoacetylmorphine. Now it is known the presence of a glucuronide metabolite only in the consumption of heroin called ATM4G and this allows a clear differentiation of the consumption of illegal heroin and poppy seed ingestion.

    Absorption

    After oral administration, opium bioavailability is poor. In the form of opioid tincture, the Cmax and AUC of opium are between 16-24 mg/ml and 3237-6727 ng/ml.h, respectively.

    Toxicity

    Some toxicity concerns from the consumption of opium are the generation of addiction, physical dependence and tolerance to the effect. Studies regarding the opioid tolerance in the treatment of chronic pain have not been systematically investigated. There are also concerns about the opioid-driven modification of endocrine function, currently reported as lower testosterone levels, loss of libido, amenorrhea and infertility.

    Indication

    Opium and its derivatives are the most commonly used medications for the treatment of acute and chronic pain. Opium and its alkaloid-derivatives can also be used as tranquilizers, antitussives and in the treatment of diarrhea. The direct use of opium is not common nowadays but the use of some of its derivatives such as morphine and codeine, as well as the use of a tincture of opium for severe diarrhea can be seen in medical practice. Illegal use of opium has been registered to be for both recreational and medicinal purposes.

    Half-life

    The half-life of opium ranges between 3-10 hours.

    Protein Binding

    The protein binding of the alkaloids that form opium, such as morphine and codeine, can range from 20-60% depending on the specific alkaloid. The highest binding proteins for opium alkaloids are albumin and beta-globulin II.

    Elimination

    Opium is a mixture of different alkaloids including morphine and codeine. After a single ingestion of opium preparations, codeine and morphine can be found excreted in urine. The presence of codeine and morphine in urine seems to be detectable 2-12 hours and 2-36 hours post administration, respectively. The urinary excretion of morphine and codeine seems to be longer as the dose of opium is increased. After multiple dosages of opium, the presence of codeine and morphine in urine could be detected even after 48 and 84 hours post administration, respectively. After ingestion of poppy seeds, it is possible to collect morphine and codeine in urine 3-25 hours and 3-22 hours after administration, respectively.

    Volume of Distribution

    Opium presents a large volume of distribution that exceeds the total body water.

    Effect Profile

    Curated + 224 Reports
    Opioid 6.6

    Strong euphoria and itching/nausea with moderate sedation, mild pain relief

    Euphoria / Warmth×3
    106.5
    Analgesia×2
    51.6
    Sedation / Relaxation×1
    63.9
    Itching / Nausea×1
    108.1
    Catalog Erowid

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 21d Baseline ~35d

    Experience Report Analysis

    Erowid BlueLight
    147 Reports
    1992–2025 Date Range
    43 With Age Data
    31 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 197 experience reports (147 Erowid + 77 Bluelight)

    197 Reports
    129 Effects Detected
    65 Positive
    42 Adverse
    22 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 65

    Contentment 44.0% 84%
    Euphoria 40.6% 89%
    Sedation 35.5% 88%
    Body High 23.4% 88%
    Anxiety Suppression 22.8% 82%
    Tactile Enhancement 22.3% 85%
    Stimulation 21.3% 82%
    Thought Deceleration 20.0% 80%
    Muscle Relaxation 20.0% 88%
    Drowsiness 20.0% 88%
    Empathy 18.3% 85%
    Music Enhancement 18.2% 80%
    Vivid Dreams 18.0% 84%
    Heaviness 16.0% 85%
    Focus Suppression 16.0% 81%
    Peace 14.0% 89%
    Sociability Enhancement 14.0% 82%
    Color Enhancement 12.2% 82%
    Joy 12.0% 88%
    Focus Enhancement 10.7% 85%

    Adverse Effects 42

    Nausea 35.6% 86%
    Itching 30.0% 89%
    Confusion 16.2% 75%
    Vomiting 16.0% 91%
    Dizziness 10.0% 78%
    Motor Impairment 9.1% 80%
    Stomach Cramps 8.0% 80%
    Body Load 8.0% 80%
    Pupil Dilation 7.6% 90%
    Headache 6.1% 83%
    Emotional Blunting 6.0% 88%
    Dysphoria 6.0% 77%
    Urinary Retention 6.0% 82%
    Disrupted Sleep Architecture 6.0% 83%
    Body Temperature Change 6.0% 85%
    Sweating 4.1% 83%
    Constipation 4.0% 80%
    Tremor 4.0% 78%
    Increased Heart Rate 3.4% 70%
    Memory Suppression 3.0% 75%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Common (n=12)
    Euphoria 75.0%
    Nausea 75.0%
    Sedation 41.7%
    Empathy 33.3%
    Stimulation 33.3%
    Tactile Enhancement 33.3%
    Dissociation 33.3%
    Anxiety Suppression 25.0%
    Hospital 25.0%
    Muscle Tension 16.7%
    Visual Distortions 16.7%
    Closed-Eye Visuals 16.7%
    Motor Impairment 16.7%
    Introspection 16.7%
    Music Enhancement 16.7%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 147 experience reports.

    Limited tier coverage — most reports fall within the Common range. Effects at other dose levels may not be represented.

    Oral dose range: 12000.0–390000.0 mg (median 125000.0 mg)
    Effect Common (n=12)
    euphoria
    75%
    nausea
    75%
    sedation
    42%
    empathy
    33%
    stimulation
    33%
    tactile enhancement
    33%
    dissociation
    33%
    anxiety suppression
    25%
    hospital
    25%
    muscle tension
    17%
    visual distortions
    17%
    closed-eye visuals
    17%
    motor impairment
    17%
    introspection
    17%
    music enhancement
    17%
    color enhancement
    17%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 125000.0 mg IQR: 12000.0–390000.0 mg n=13

    Real-World Dose Distribution

    62K Doses

    From 141 individual dose entries

    Oral (n=18)

    Median: 4000.0mg 25th: 275.0mg 75th: 8875.0mg 90th: 11300.0mg
    mg/kg median: 77.16 mg/kg 75th: 116.667

    Smoked (n=12)

    Median: 750.0mg 25th: 437.5mg 75th: 2940.0mg 90th: 3000.0mg
    mg/kg median: 8.479 mg/kg 75th: 14.697

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 3739.214 mg/kg IQR: 785.124–6470.588 mg/kg n=12

    Smoked

    Median: 39.63 mg/kg IQR: 8.475–45.984 mg/kg n=5

    Redose Patterns

    Redosing behavior across 115 reports

    12.2% Redosed
    1.1 Avg Doses

    Opioid Equivalence (MME)

    NIH HEAL 2024 & CDC 2022
    ⚠ Citation & Disclaimer: Conversion factors sourced from the NIH HEAL Initiative MME Calculator (Adams et al., PAIN 2025), the CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain, and the MDCalc MME Calculator. These are approximate equianalgesic ratios for educational reference only. Individual responses vary significantly based on genetics, tolerance, cross-tolerance, and route of administration. This is not medical advice. Do not use these conversions to adjust opioid dosing without professional medical guidance.
    10 mg Opium 10 mg Morphine (oral)
    MME factor 1.0×

    Opium 10 mg oral ≈ 10 mg Morphine oral (10 mg morphine per 1 mL liquid opium)

    Contains approximately 10 mg morphine per 1 mL of liquid opium.
    ← Back to Opium